Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 1

Status

Active not recruiting 2Withdrawn 1

Sponsor Class

OTHER 13NETWORK 5NIH 4INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 12Other hematologic neoplasm 11Breast 11Classical hematology 4Thoracic 3Plasma cell 3Other solid neoplasm 3Myeloid 3Sarcoma 2Gastrointestinal 2Dermatologic 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 3

Interventions

Carboplatin 538Pemetrexed 392pembrolizumab 369Cisplatin 354Paclitaxel 285Docetaxel 240Gemcitabine 168Nivolumab 158Erlotinib Hydrochloride 147Bevacizumab 114atezolizumab 103osimertinib 98durvalumab 92Etoposide 89Gefitinib 68130-nm albumin-bound paclitaxel 65Cetuximab 64Ipilimumab 60Drug Therapy 51Topotecan 48Injections 43Afatinib 41tislelizumab 40Cyclophosphamide 39Albumin-Bound Paclitaxel 37Vinorelbine 36Crizotinib 34cemiplimab 31icotinib 26Radiotherapy 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Filgrastim × Thoracic × Clear all
NCT06212752 2025-11-12

MK-3475A-D77

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
39 enrolled 21 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05722015 2025-09-11

MK-3475A-D77

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
377 enrolled 17 charts 1 FDA
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01938456 2014-07-28

Safety and Tolerability of Trametinib in Combination With Docetaxel in Japanese Subjects With Non-small Cell Lung Cancer

GlaxoSmithKline

Phase 1 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡